Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of Additional Notices of Allowance With Claims Covering RAVICTI® (glycerol phenylbutyrate) Oral Liquid

- Will Represent the Eighth and Ninth U.S. Patents to be Listed in the Orange Book for RAVICTI -

DUBLIN, Ireland, May 08, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP) today announced that it has received two Notices of Allowance from the United States Patent and Trademark Office for U.S. patent application numbers 15/457,643 and 15/687,132, both entitled "Methods of Therapeutic Monitoring of Nitrogen Scavenging Drugs” that cover Horizon's U.S. approved medicine RAVICTI (glycerol phenylbutyrate) Oral Liquid.

These Notices of Allowance conclude the substantive examination of the patent applications and will result in the issuance of two U.S. patents after administrative processes are completed.  The U.S. patents scheduled to issue from these applications will expire on September 22, 2030.  After issuance, Horizon plans to list the U.S. patents in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.

About RAVICTI
RAVICTI was first approved in the U.S. in February 2013 for the chronic management of adult and pediatric patients ≥2 years of age with UCDs that cannot be managed by dietary protein restriction and/or amino acid supplementation alone.  In April 2017, the indication for RAVICTI was expanded to include children as young as two months of age.  Click here for more information about RAVICTI.

RAVICTI® (glycerol phenylbutyrate) Oral Liquid

INDICATIONS AND USAGE
RAVICTI is a nitrogen-binding agent indicated for chronic management of patients 2 months of age and older with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.  RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements).

LIMITATIONS OF USE

• RAVICTI is not indicated for the treatment of acute hyperammonemia in patients with UCDs because rapidly acting interventions are essential to reduce plasma ammonia levels.
• The safety and efficacy of RAVICTI for the treatment of N-acetylglutamate synthase (NAGS) deficiency has not been established.

DETAILED IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

• Patients less than 2 months of age:  Children less than 2 months of age may have immature pancreatic exocrine function, which could impair hydrolysis of RAVICTI, leading to impaired absorption of phenylbutyrate and hyperammonemia.
• Patients with known hypersensitivity to phenylbutyrate:  Reactions include wheezing, dyspnea, coughing, hypotension, flushing, nausea and rash.

WARNINGS AND PRECAUTIONS

• Neurotoxicity:  Phenylacetate (PAA), the major metabolite of RAVICTI, may be toxic at levels of 500 µg/mL or greater.  Reduce RAVICTI dosage if symptoms of neurotoxicity, including vomiting, nausea, headache, somnolence or confusion, are present in the absence of high ammonia or other intercurrent illnesses.
• Reduced phenylbutyrate absorption in pancreatic insufficiency or intestinal malabsorption:  Low or absent pancreatic enzymes or intestinal disease resulting in fat malabsorption may result in reduced or absent digestion of RAVICTI and/or absorption of phenylbutyrate and reduced control of plasma ammonia.  Monitor ammonia levels closely.

USE IN SPECIFIC POPULATIONS

ADVERSE REACTIONS

• In ≥10% of adult patients:  diarrhea, flatulence, and headache occurred during 4-week treatment (n=44) with RAVICTI; nausea, vomiting, diarrhea, decreased appetite, dizziness, headache and fatigue occurred during 12-month treatment (n=51) with RAVICTI.
• In ≥10% of pediatric patients ages 2 to 17 years:  upper abdominal pain, rash, nausea, vomiting, diarrhea, decreased appetite and headache occurred during 12-month treatment (n=26) with RAVICTI.
• In ≥10% of pediatric patients ages 2 months to less than 2 years:  neutropenia, vomiting, diarrhea, pyrexia, hypophagia, cough, nasal congestion, rhinorrhea, rash and papule occurred during 12-month treatment (n=6) with RAVICTI.

DRUG INTERACTIONS

• Corticosteroids, valproic acid or haloperidol may increase plasma ammonia level.  Monitor ammonia levels closely.
• Probenecid may affect renal excretion of metabolites of RAVICTI, including phenylacetylglutamine (PAGN) and PAA.
• CYP3A4 substrates with narrow therapeutic index (e.g., alfentanil, quinidine, cyclosporine): RAVICTI may decrease exposure to the concomitant drug.
• Midazolam:  Use of RAVICTI decreased exposure of midazolam with concomitant use.

Click here to download a copy of the RAVICTI Full Prescribing Information.

About Urea Cycle Disorders (UCDs)
A UCD is a rare genetic disorder that affects approximately 1 in 35,000 live births in the United States.  It is caused by an enzyme deficiency in the urea cycle, a process that is responsible for converting excess ammonia from the bloodstream and ultimately removing it from the body.  Because of this, people with a UCD experience hyperammonemia, or elevated ammonia levels in their blood, that can then reach the brain and cause irreversible brain damage, coma or death.  UCD symptoms may first occur at any age depending on the severity of the disorder, with more severe defects presenting earlier in life.

About Horizon Pharma plc
Horizon Pharma plc is focused on researching, developing and commercializing innovative medicines that address unmet treatment needs for rare and rheumatic diseases.  By fostering a growing pipeline of medicines in development and exploring all potential uses for currently marketed medicines, we strive to make a powerful difference for patients, their caregivers and physicians.  For us, it’s personal:  by living up to our own potential, we are helping others live up to theirs.  For more information, please visit www.horizonpharma.com, follow us @HZNPplc on Twitter or like us on Facebook.

Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the issuance of patents based on the Notices of Allowance from the U.S. Patent and Trademark Office, the expected term of the patents, if issued, potential patent protection for RAVICTI and plans to list newly issued patents in the FDA's Orange Book.  These forward-looking statements are based on management expectations and assumptions as of the date of this press release, and actual results may differ materially from those in these forward-looking statements as a result of various factors.  These factors include risks regarding whether the administrative processes required for the issuance of patents as indicated in the Notices of Allowance will be completed in a timely manner or at all, whether the patents, if issued as indicated in the Notices of Allowance, will provide sufficient protection and market exclusivity for RAVICTI, whether any patents covering RAVICTI may be challenged, invalidated, infringed or circumvented by third parties and other factors described in Horizon's filings with the United States Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in those filings.  Forward-looking statements speak only as of the date of this press release and Horizon does not undertake any obligation to update or revise these statements, except as may be required by law.

Contacts:
Tina Ventura
Senior Vice President, Investor Relations
Investor-relations@horizonpharma.com

Ruth Venning
Executive Director, Investor Relations
Investor-relations@horizonpharma.com

U.S. Media Contact:
Geoffrey Curtis
Senior Vice President, Corporate Affairs and Chief Communications Officer
media@horizonpharma.com

Ireland Media Contact:
Ray Gordon
Gordon MRM 
ray@gordonmrm.ie